Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:2036
Published online before print May 24, 2007, doi: 10.1161/STROKEAHA.107.489856
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/7/2036    most recent
STROKEAHA.107.489856v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dietrich, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dietrich, H. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Related Collections
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology
Right arrow Animal models of human disease
Right arrow Risk Factors
Right arrow Brain Circulation and Metabolism
Right arrow Genetically altered mice
Right arrow Risk Factors for Stroke
Right arrowRelated Article

(Stroke. 2007;38:2036.)
© 2007 American Heart Association, Inc.


Editorials

Apolipoprotein E in Hypercholesteremia and Beyond

Hans H. Dietrich, PhD

From the Department of Neurological Surgery, Washington University Medical School, St. Louis, Mo.

Correspondence to Hans H. Dietrich, Department of Neurological Surgery, Washington University Medical School, 660 South Euclid Avenue, St. Louis, MO 63110. E-mail dietrich_h{at}wustl.edu

See related article, pages 2136–2141.

Apolipoprotein E (ApoE) is a protein related to the receptor-mediated removal of lipids from the blood stream. When ApoE-deficient mice were introduced,1,2 these animals displayed hypercholesteremia and increased atherosclerosis, providing a new tool to study hypercholesteremia-related pathological mechanisms and have been used extensively ever since. With respect to the cerebral circulation, it is interesting to note that not until 1998 did the first study on ApoE deficiency and cerebral ischemia appear3 and only 5 more studies, mostly related to stroke and inflammation, followed to this date in this field.

Kitayama et al are interested to study the effect of hypercholesteremia on pial arteriolar vasomotor responses. They used hemizygous (ApoE+/–) animals as their control (rather than homozygotes) and ApoE-deficient mice (ApoE–/–) that were fed normal or high-fat diets. The first observation is that the hemizygous control animals have similar cholesterol levels as homozygous mice, indicating that one functioning allel of ApoE may be sufficient to keep blood cholesterol at normal levels. After demonstrating that especially severe hypercholesteremia adversely affects pial arteriolar dilation, the group continues to show that scavenging oxygen radicals with Tempol or inhibiting NADPH oxidase with Apocynin can restore vessel dilation to Acetylcholine at the lower concentration tested. But at the higher concentration used, Acetylcholine did not achieve dilation comparable to control animals. This seems to indicate that another factor besides oxygen radicals affects the vascular dilation to Acetylcholine in severely hypercholesteremic arterioles. If there is another factor and what this factor could be need to be studied further. Lack of response to external nitric oxide, though, does not seem to be deficient.

Another aspect of the study of ApoE effects in mice is that we now have mouse models with the mouse ApoE gene replaced with human ApoE alleles. The study of such alleles has come to the forefront in many research areas including stroke and Alzheimer disease.4,5 Thus understanding and knowing the physiological effects of mouse ApoE will help us to determine the effects and consequences of introducing human ApoE alleles into this organism including vascular regulation. It is therefore possible that the observations and results provided by Kitayama et al will have implications beyond the study of hypercholesteremia.

Acknowledgments

Sources of Funding

H.H.D. is supported by NIH grants NS 32636, NS30555, and HL041250.

Disclosures

None.

Footnotes

The opinions in this editorial are not necessarily those of the editors or of the American Heart Association.

References

  1. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992; 258: 468–471.[Abstract/Free Full Text]
  2. Plump AS, Smith JD, Hayek T, alto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992; 71: 343–353.[CrossRef][Medline] [Order article via Infotrieve]
  3. Bart RD, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Regional CBF in apolipoprotein E-deficient and wild type mice during focal cerebral ischemia. Neuroreport. 1998; 9: 2615–2620.[Medline] [Order article via Infotrieve]
  4. Sudlow C, Martinez Gonzalez NA, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke. 2006; 37: 364–370.[Abstract/Free Full Text]
  5. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry. 2006; 11: 721–736.[CrossRef][Medline] [Order article via Infotrieve]

Related Article:

Cerebral Vascular Dysfunction During Hypercholesterolemia
Jiro Kitayama, Frank M. Faraci, Steven R. Lentz, and Donald D. Heistad
Stroke 2007 38: 2136-2141. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/7/2036    most recent
STROKEAHA.107.489856v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dietrich, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dietrich, H. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Related Collections
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology
Right arrow Animal models of human disease
Right arrow Risk Factors
Right arrow Brain Circulation and Metabolism
Right arrow Genetically altered mice
Right arrow Risk Factors for Stroke
Right arrowRelated Article